Pyogenic Liver Abscesses in Patients With Malignant Disease

Authors:
  • YJYi-Yin Jan
    Yi-Yin Jan
  • LJLong-Bin Jeng
    Long-Bin Jeng
  • THTsang-Long Hwang
    Tsang-Long Hwang
  • TCTzu-Chieh Chao
    Tzu-Chieh Chao
  • RCRong-Nan Chien
    Rong-Nan Chien
  • MCMiin-Fu Chen
    Miin-Fu Chen

Abstract
PYOGENIC LIVER abscess was recognized as early as the era of Hippocrates (460-370 BC). In 1938, Ochsner et al1 noted portal venous suppuration secondary to acute appendicitis in 34% of a collected series of 575 cases with pyogenic liver abscess. By 1960, Sherman and Robbins2 had noted that biliary tract disease and malignant disease supplanted portal vein seeding as the most common mode of bacterial entry into the liver. During the last decade, despite advances in antibiotics, microbiologic study, diagnostic modalities, and nonoperative percutaneous drainage, the mortality rate has remained from 12% to 26% and from 2% to 15% in surgical patients and in those with a percutaneous drain, respectively.3-7 These unfavorable results are mainly attributed to the increasing number of patients with neoplastic disease, biliary tract disease, multiple liver abscess, old age, and immunocompromise following various anticancer treatments. Reports from institutions worldwide have indicated that malignant disease is the major risk factor for liver abscess,3,4,7,8 although Marcus et al5 claim that there is still a good prognosis even in patients who have cancer and a liver abscess. The aim of this study was to clarify the clinical course of pyogenic liver abscess in patients with different types of cancer. We also compared outcomes in abscesses caused by hepatopancreatobiliary malignant disease and other malignant disease.

This publication has 8 references indexed in Scilit: